ArticleGenes & cancer2016

Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia.

Sandip N Chakraborty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.